Screening for new red blood cell alloantibodies after transfusion in patients with sickle cell disease.
alloimmunization
antibody evanescence
sickle cell disease
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
22
04
2021
received:
27
12
2020
accepted:
22
04
2021
pubmed:
19
5
2021
medline:
20
8
2021
entrez:
18
5
2021
Statut:
ppublish
Résumé
Patients with sickle cell disease (SCD) are frequent recipients of red blood cell (RBC) transfusions and are at risk for RBC alloimmunization. RBC alloimmunization is diagnosed by identifying RBC alloantibodies as part of pre-transfusion testing, but this testing fails to detect alloantibodies that have evanesced. It may be beneficial to screen for new RBC alloantibody development after transfusion before possible antibody evanescence. Our institution started a new initiative for episodically transfused patients with SCD to obtain at least one antibody screen 2-6 months after transfusion as part of their clinical care. A database was created to prospectively track all transfused patients for 1 year and their post-transfusion antibody screen results. Patients received prophylactically CEK-matched RBC units. During the study year, 138 patients with SCD received a total of 242 RBC transfusions. Patients with a history of an RBC alloantibody (n = 13, 9.4%) had previously received more RBC units than non alloimmunized patients (median 11 vs. 2 RBC units, p = .0002). A total of 337 post-transfusion antibody screens were obtained in 127 patients (92.0%) with 110 patients (79.7%) having at least one antibody screen 2-6 months post-transfusion. With this prospective testing, two new RBC alloantibodies (anti-C and -M) were identified in two patients. It is feasible to test for new RBC alloantibody development in most episodically transfused patients with SCD as part of their routine care. The yield of this screening appears low with CEK matching, but it could still provide important information for individual patients.
Sections du résumé
BACKGROUND
Patients with sickle cell disease (SCD) are frequent recipients of red blood cell (RBC) transfusions and are at risk for RBC alloimmunization. RBC alloimmunization is diagnosed by identifying RBC alloantibodies as part of pre-transfusion testing, but this testing fails to detect alloantibodies that have evanesced. It may be beneficial to screen for new RBC alloantibody development after transfusion before possible antibody evanescence.
STUDY DESIGN AND METHODS
Our institution started a new initiative for episodically transfused patients with SCD to obtain at least one antibody screen 2-6 months after transfusion as part of their clinical care. A database was created to prospectively track all transfused patients for 1 year and their post-transfusion antibody screen results. Patients received prophylactically CEK-matched RBC units.
RESULTS
During the study year, 138 patients with SCD received a total of 242 RBC transfusions. Patients with a history of an RBC alloantibody (n = 13, 9.4%) had previously received more RBC units than non alloimmunized patients (median 11 vs. 2 RBC units, p = .0002). A total of 337 post-transfusion antibody screens were obtained in 127 patients (92.0%) with 110 patients (79.7%) having at least one antibody screen 2-6 months post-transfusion. With this prospective testing, two new RBC alloantibodies (anti-C and -M) were identified in two patients.
CONCLUSION
It is feasible to test for new RBC alloantibody development in most episodically transfused patients with SCD as part of their routine care. The yield of this screening appears low with CEK matching, but it could still provide important information for individual patients.
Substances chimiques
Isoantibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2255-2264Informations de copyright
© 2021 AABB.
Références
Smith-Whitley K, Thompson AA. Indications and complications of transfusions in sickle cell disease. Pediatr Blood Cancer. 2012;59:358-64.
Inati A, Mansour AG, Sabbouh T, Amhez G, Hachem A, Abbas HA. Transfusion therapy in children with sickle cell disease. J Pediatr Hematol Oncol. 2017;39:126-32.
Thame JR, Hambleton IR, Serjeant GR. RBC transfusion in sickle cell anemia (HbSS): experience from the Jamaican Cohort Study. Transfusion. 2001;41:596-601.
Chou ST, Alsawas M, Fasano RM, Field JJ, Hendrickson JE, Howard J, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4:327-55.
Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033-48.
Sharma D, Ogbenna AA, Kassim A, Andrews J. Transfusion support in patients with sickle cell disease. Semin Hematol. 2020;57:39-50.
DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371:699-710.
Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339:5-11.
Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353:2769-78.
Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381:509-19.
King KE, Shirey RS, Lankiewicz MW, Young-Ramsaran J, Ness PM. Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients' red cells. Transfusion. 1997;37:376-81.
Talano JA, Hillery CA, Gottschall JL, Baylerian DM, Scott JP. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics. 2003;111:e661-5.
Chadebech P, Habibi A, Nzouakou R, Bachir D, Meunier-Costes N, Bonin P, et al. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Transfusion. 2009;49:1785-92.
Vidler JB, Gardner K, Amenyah K, Mijovic A, Thein SL. Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience. Br J Haematol. 2015;169:746-53.
de Montalembert M, Dumont MD, Heilbronner C, Brousse V, Charrara O, Pellegrino B, et al. Delayed hemolytic transfusion reaction in children with sickle cell disease. Haematologica. 2011;96:801-7.
Petz LD, Calhoun L, Shulman IA, Johnson C, Herron RM. The sickle cell hemolytic transfusion reaction syndrome. Transfusion. 1997;37:382-92.
Tormey CA, Stack G. The persistence and evanescence of blood group alloantibodies in men. Transfusion. 2009;49:505-12.
Tormey CA, Hendrickson JE. Transfusion-related red blood cell alloantibodies: induction and consequences. Blood. 2019;133:1821-30.
Schonewille H, Haak HL, van Zijl AM. RBC antibody persistence. Transfusion. 2000;40:1127-31.
Hauser RG, Esserman D, Karafin MS, Tan S, Balbuena-Merle R, Spencer BR, et al. The evanescence and persistence of RBC alloantibodies in blood donors. Transfusion. 2020;60:831-9.
Reverberi R. The persistence of red cell alloantibodies. Blood Transfus. 2008;6:225-34.
Ramsey G, Smietana SJ. Long-term follow-up testing of red cell alloantibodies. Transfusion. 1994;34:122-4.
Ramsey G, Larson P. Loss of red cell alloantibodies over time. Transfusion. 1988;28:162-5.
Williams LA 3rd, Lorenz RG, Tahir A, Pham HP, Marques MB. High percentage of evanescent red cell antibodies in patients with sickle cell disease highlights need for a national antibody database. South Med J. 2016;109:588-91.
Stack G, Tormey CA. Detection rate of blood group alloimmunization based on real-world testing practices and kinetics of antibody induction and evanescence. Transfusion. 2016;56:2662-7.
Sloan SR. The importance of antibody screens after transfusions. Transfusion. 2016;56:2653-4.
Redman M, Regan F, Contreras M. A prospective study of the incidence of red cell allo-immunisation following transfusion. Vox Sang. 1996;71:216-20.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377-81.
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
Nickel RS, Hendrickson JE, Fasano RM, Meyer EK, Winkler AM, Yee MM, et al. Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series. Transfusion. 2016;56:107-14.
Kacker S, Ness PM, Savage WJ, Frick KD, Shirey RS, King KE, et al. Cost-effectiveness of prospective red blood cell antigen matching to prevent alloimmunization among sickle cell patients. Transfusion. 2014;54:86-97.
Kacker S, Ness PM, Savage WJ, Frick KD, Shirey RS, King KE, et al. Economic evaluation of a hypothetical screening assay for alloimmunization risk among transfused patients with sickle cell disease. Transfusion. 2014;54:2034-44.
Gehrie EA, Ness PM, Bloch EM, Kacker S, Tobian AAR. Medical and economic implications of strategies to prevent alloimmunization in sickle cell disease. Transfusion. 2017;57:2267-76.
Weisman JK, Diamond CE, Kappa S, Nickel RS. Transcranial doppler screening adherence among children with sickle cell anemia seen in the emergency department. J Pediatr. 2020;217:172-6.e1.
Pecker LH, Kappa S, Greenfest A, Darbari DS, Nickel RS. Targeted hydroxyurea education after an emergency department visit increases hydroxyurea use in children with sickle cell anemia. J Pediatr. 2018;201:221-8.e16.
Osby M, Shulman IA. Phenotype matching of donor red blood cell units for nonalloimmunized sickle cell disease patients: a survey of 1182 North American laboratories. Arch Pathol Lab Med. 2005;129:190-3.
Dunbar LN, Coleman Brown L, Rivera DR, Hartzema AG, Lottenberg R. Transfusion practices in the management of sickle cell disease: a survey of Florida hematologists/oncologists. ISRN Hematol. 2012;2012:524513.
Fasano RM, Branscomb J, Lane PA, Josephson CD, Snyder AB, Eckman JR. Transfusion service knowledge and immunohaematological practices related to sickle cell disease and thalassemia. Transfus Med. 2019;29:185-92.
Tebuka E, Charles M, Bhuko JO. Prevalence and risk factors for red blood cell alloimmunisation among sickle cell patients in Mwanza City. Tanzania Afr J Lab Med. 2020;9:823.
Boateng LA, Campbell AD, Davenport RD, Osei-Akoto A, Hugan S, Asamoah A, et al. Red blood cell alloimmunization and minor red blood cell antigen phenotypes in transfused Ghanaian patients with sickle cell disease. Transfusion. 2019;59:2016-22.
Natukunda B, Schonewille H, Ndugwa C, Brand A. Red blood cell alloimmunization in sickle cell disease patients in Uganda. Transfusion. 2010;50:20-5.
Diop S, Pirenne F. Transfusion and sickle cell anemia in Africa. Transfus Clin Biol. 2021;28:143-5.
Spanos T, Karageorga M, Ladis V, Peristeri J, Hatziliami A, Kattamis C. Red cell alloantibodies in patients with thalassemia. Vox Sang. 1990;58:50-5.
Tatari-Calderone Z, Minniti CP, Kratovil T, Stojakovic M, Vollmer A, Barjaktarevic I, et al. rs660 polymorphism in Ro52 (SSA1; TRIM21) is a marker for age-dependent tolerance induction and efficiency of alloimmunization in sickle cell disease. Mol Immunol. 2009;47:64-70.
Karafin MS, Westlake M, Hauser RG, Tormey CA, Norris PJ, Roubinian NH, et al. Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database. Br J Haematol. 2018;181:672-81.
Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion. 2002;42:37-43.
Rosse WF, Gallagher D, Kinney TR, Castro O, Dosik H, Moohr J, et al. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood. 1990;76:1431-7.
Hendrickson JE, Desmarets M, Deshpande SS, Chadwick TE, Hillyer CD, Roback JD, et al. Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells. Transfusion. 2006;46:1526-36.
Hendrickson JE, Chadwick TE, Roback JD, Hillyer CD, Zimring JC. Inflammation enhances consumption and presentation of transfused RBC antigens by dendritic cells. Blood. 2007;110:2736-43.
Smith NH, Hod EA, Spitalnik SL, Zimring JC, Hendrickson JE. Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs. Blood. 2012;119:1566-9.
Fasano RM, Booth GS, Miles M, Du L, Koyama T, Meier ER, et al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol. 2015;168:291-300.
Sins JW, Biemond BJ, van den Bersselaar SM, Heijboer H, Rijneveld AW, Cnossen MH, et al. Early occurrence of red blood cell alloimmunization in patients with sickle cell disease. Am J Hematol. 2016;91:763-9.
Allali S, Peyrard T, Amiranoff D, Cohen JF, Chalumeau M, Brousse V, et al. Prevalence and risk factors for red blood cell alloimmunization in 175 children with sickle cell disease in a French university hospital reference centre. Br J Haematol. 2017;177:641-7.
Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Westhoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013;122:1062-71.
Nickel RS, Horan JT, Fasano RM, Meyer E, Josephson CD, Winkler AM, et al. Immunophenotypic parameters and RBC alloimmunization in children with sickle cell disease on chronic transfusion. Am J Hematol. 2015;90:1135-41.
Samarah F, Srour MA, Yaseen D, Dumaidi K. Frequency of red blood cell alloimmunization in patients with sickle cell disease in palestine. Adv Hematol. 2018;2018:5356245.
Rodrigues C, Sell AM, Guelsin GAS, Higa TT, Pagliarini ESS, Macedo LC, et al. HLA polymorphisms and risk of red blood cell alloimmunisation in polytransfused patients with sickle cell anaemia. Transfus Med. 2017;27:437-43.
Regalado-Artamendi I, Pérez-Corral AM, García-Morín M, Cela E, Beléndez C, Bardón-Cancho EJ, et al. Complete RH and Kell matching related to low alloimmunisation risk in sickle cell disease: prevalence and risk factors of alloimmunisation in a Spanish Tertiary Care National Reference Centre. Blood Transfus. 2020. https://doi.org/10.2450/2020.0096-20.
Murao M, Viana MB. Risk factors for alloimmunization by patients with sickle cell disease. Braz J Med Biol Res. 2005;38:675-82.
Balbuena-Merle R, Santhanakrishnan M, Devine L, Gibb DR, Tormey CA, Siddon AJ, et al. Characterization of circulating and cultured Tfh-like cells in sickle cell disease in relation to red blood cell alloimmunization status. Transfus Apher Sci. 2020;59:102778.
Vingert B, Tamagne M, Habibi A, Pakdaman S, Ripa J, Elayeb R, et al. Phenotypic differences of CD4(+) T cells in response to red blood cell immunization in transfused sickle cell disease patients. Eur J Immunol. 2015;45:1868-79.
Zhong H, Bao W, Friedman D, Yazdanbakhsh K. Hemin controls T cell polarization in sickle cell alloimmunization. J Immunol. 2014;193:102-10.
Bao W, Zhong H, Manwani D, Vasovic L, Uehlinger J, Lee MT, et al. Regulatory B-cell compartment in transfused alloimmunized and non-alloimmunized patients with sickle cell disease. Am J Hematol. 2013;88:736-40.
Godefroy E, Liu Y, Shi P, Mitchell WB, Cohen D, Chou ST, et al. Altered heme-mediated modulation of dendritic cell function in sickle cell alloimmunization. Haematologica. 2016;101:1028-38.
Tatari-Calderone Z, Tamouza R, Le Bouder GP, Dewan R, Luban NL, Lasserre J, et al. The association of CD81 polymorphisms with alloimmunization in sickle cell disease. Clin Dev Immunol. 2013;2013:937846.
Sippert EA, Visentainer JE, Alves HV, Rodrigues C, Gilli SC, Addas-Carvalho M, et al. Red blood cell alloimmunization in patients with sickle cell disease: correlation with HLA and cytokine gene polymorphisms. Transfusion. 2017;57:379-89.
Williams LM, Qi Z, Batai K, Hooker S, Hall NJ, Machado RF, et al. A locus on chromosome 5 shows African ancestry-limited association with alloimmunization in sickle cell disease. Blood Adv. 2018;2:3637-47.
Schonewille H, van de Watering LM, Loomans DS, Brand A. Red blood cell alloantibodies after transfusion: factors influencing incidence and specificity. Transfusion. 2006;46:250-6.